Penny Asbell is an Ophthalmology physician. OpenAlex indexes 403 publications with 10,629 citations (h-index 53); ClinicalTrials.gov lists 6 registered studies matched to this name. By OpenAlex citation count, this profile ranks in the top 5% of Ophthalmology profiles in the findmyKOL directory.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
930 Madison Ave Ste 200
Memphis, TN 38163
Telephone
901-448-6650Registry record last updated 1 Feb 2019.
Clinical trials
- Safety and Effectiveness of Corneal Crosslinking (CXL): Keratoconus and Post-Refractive Ectasia
Sponsor: Icahn School of Medicine at Mount Sinai
- Dry Eye Assessment and Management Study
Sponsor: University of Pennsylvania
- Systane Ultra Versus Maxidex Versus Saline
Sponsor: Icahn School of Medicine at Mount Sinai
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
16 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Dompe Farmaceutici S.p.A.Program year20252 payments
- Harrow Eye, LLCProgram year20253 payments
- Dompe US, Inc.Program year20256 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2021)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Sensory organs
71.2%Corticosteroid45.9%Prednisolone Acetate100%Part D≥39 patientsNonsteroidal Anti-inflammatory Drug13.5%Prolensa100%Part D≥13 patients+ 1 more class in this area
Anti-infectives
28.8%Fluoroquinolone Antibacterial28.8%Moxifloxacin100%Part D≥20 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
1 NIH research award on record, funded 2020–2020 per NIH RePORTER. The latest:
- Dry Eye Evaluation and Management (DREAM)
University of Tennessee Health Sci Ctr
FY2020$129,730U10EY022881
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
Similar KOLs
Other experts from the same institution or the same specialty.
No other directory profiles share this institution yet.
Emily Chew, MD
National Eye Institute
Robert Weinreb, MD
University of California San Diego
Harry Quigley, MD
Johns Hopkins University School of Medicine
Joel Schuman, MD
Wills Eye Hospital
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”